EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter, randomized, double-blind, placebo-controlled trial of interferon-alpha with and without amantadine as treatment for IFN-alpha non-responders with chronic hepatitis C



Multicenter, randomized, double-blind, placebo-controlled trial of interferon-alpha with and without amantadine as treatment for IFN-alpha non-responders with chronic hepatitis C



Gastroenterology 118(4 Suppl 2 Part 2): AASLD A149, April




(PDF 0-2 workdays service: $29.90)

Accession: 035349991

Download citation: RISBibTeXText



Related references

Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine-sulfat in primary IFN-alpha non-responders with chronic hepatitis C. Hepatology 32(4 Pt 2): 354A, October, 2000

A randomized, double-blind, placebo-controlled trial of interferon-alpha and amantadine versus interferon-alpha alone in the treatment of patients with chronic hepatitis C. Digestive Diseases and Sciences 47(7): 1655-1656, 2002

Double-blind, multicenter, placebo-controlled trial of interferon alpha-2B plus ribavirin versus interferon alpha-2B for retreatment of relapsers and non-responders with chronic hepatitis C who failed previous treatment with interferon. Gastroenterology 116(4 PART 2): A1202, April, 1999

Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C. Journal of Viral Hepatitis 8(4): 276-283, 2001

Multicenter, placebo-controlled, double-blind trial of interferon alpha-2b plus ribavirin vs interferon alone for retreatment of non-responders and relapsers with chronic hepatitis C who have failed previous treatment with interferon A 48 week review. Hepatology 30(4 PART 2): 201A, 1999

A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy. Journal of Hepatology 34(1): 128-133, January, 2001

Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. European Journal of Gastroenterology & Hepatology 19(8): 639-646, 2007

Double-blind, placebo-controlled trial of interferon alpha-2b plus ribavirin versus interferon alpha-2b for retreatment of patients with chronic hepatitis C who failed previous treatment with interferon alpha. Hepatology 28(4 PART 2): 703A, 1998

Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 32(4 Pt 1): 835-841, 2000

Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: A multi-center, randomized, double-blind, placebo-controlled trial. Hepato-Gastroenterology 45(21): 797-804, May-June, 1998

Low-dose oral interferon-alpha in the treatment of chronic viral hepatitis type B: A double-blind, randomized, placebo-controlled, clinical trial. Current Therapeutic Research 61(5): 245-254, 2000

Interferon alfa-2a and amantadine or placebo in IFN-naive patients with chronic hepatitis C A double-blind, randomized, placebo-controlled trial. Hepatology 34(4 Pt 2): 331A, October, 2001

Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology 35(2): 447-454, 2002

A randomized, double blind, placebo controlled trial of interferon-alfa and amantadine versus interferon-alfa alone in the treatment of chronic hepatitis C. Gastroenterology 118(4 Suppl 2 Part 2): AASLD A148, April, 2000

Triple therapy with amantadine sulphate plus ribavirin and interferon-alpha in previously untreated patients with chronic hepatitis C Results of a double-blind, placebo-controlled Trial. Journal of Hepatology 36(Supplement 1): 3, April, 2002